Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

CUDC-305 is an orally bioavailable inhibitor of heat shock protein 90 (Hsp90; Item Nos. 22734 | 22735).1 It binds to Hsp90α and Hsp90β (IC50s = 100 and 103 nM for purified protein, respectively) as well as Hsp90 isolated from non-small cell lung cancer (NSCLC) cells resistant to erlotinib (Item No. 10483; IC50 = 70 nM).1,2 CUDC-305 induces degradation of Hsp90 client proteins in BT-474 breast cancer cells and inhibits proliferation of 40 human cancer cell lines (IC50s = 0.04-0.9 µM).1 It also reduces the levels of several oncoproteins including Akt and phosphorylated Akt, and ERK1/2 and phosphorylated ERK1/2 in a variety of cancer cell lines. CUDC-305 (40-160 mg/kg) dose-dependently reduces tumor growth in a U87MG glioblastoma mouse xenograft model and, when administered at a dose of 160 mg/kg, prolongs survival in a U87MG mouse orthotopic model.
WARNING This product is not for human or veterinary use.
1. CUDC-
2. Targeting heat shock protein 90 with CUDC-